ArticleClinical ophthalmology (Auckland, N.Z.)2025
Performance and Safety of Minimally Invasive Nasal Trabeculostomy (MINT™) in Open-Angle Glaucoma: A 12-month Open-Label Study on Patients with No Other Glaucoma Surgeries.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05638906 (Minimally Invasive Nasal Trabeculostomy - Performance and Safety Evaluation Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Minimally Invasive Nasal Trabeculostomy - Performance and Safety Evaluation Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Minimally invasive nasal trabeculostomy (MINT™) is an ab interno, stent-less, trabecular-opening glaucoma procedure designed to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG). This 12-month, prospective, single-arm, open-label study aimed to evaluate the performance and safety of the MINT device in patients with OAG with uncontrolled IOP. Methods: Eligible patients had uncontrolled OAG (IOP ≥21 mmHg with maximum tolerated glaucoma medications). The primary efficacy endpoint was the proportion of patients achieving ≥20% IOP reduction from baseline on the same or fewer medications at Week 24. Secondary efficacy endpoints were mean change in IOP from baseline at Weeks 24 and 52, and the proportion of patients achieving a ≥20% reduction in IOP from baseline on the same number or fewer medications at Week 52. Results: The procedures were performed between 11 April 2022 and 24 October 2022 by one surgeon (LV) at the Ophthalmologic Center after S.V. Malayan, Yerevan, Armenia. Sixty-six eyes of 66 patients underwent the procedure; 63 and 56 patients completed the Week 24 and 52 visits, respectively. Fifty-two of 63 (82.5%) patients achieved the primary endpoint. The mean (standard deviation) baseline IOP (22.7 ± 1.4 mmHg) was reduced by 34.2% to 15.0 ± 2.8 mmHg at Week 24, and by 35.3% to 14.7 ± 2.4 mmHg at Week 52. Twenty-two adverse events (AEs) were reported, including 20 postoperative ocular AEs in 15 patients. Ocular AEs were non-serious and mild. Conclusion: In this patient population, the MINT device achieved an 82.5% success rate as per the FDA-recommended primary endpoint. IOP was lowered from baseline, below the European Glaucoma Society target range for early glaucoma (<20 mmHg) in 98.4% of patients and moderate glaucoma (<17 mmHg) in 68.3% of patients. No intraoperative and minimal postoperative complications were reported. Clinical Trial Registration: https://clinicaltrials.gov/study/NCT05638906 (NCT05638906).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.